P

    Procept Biorobotics Corp (PRCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $21.20
    +0.37 (+1.78%)

    Market Cap: $1.19B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    +0.36%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.42 - $-0.34
    10 analysts
    EPS Revisions
    1
    0
    7d
    0
    7
    30d
    EPS Estimate Drift
    90d ago$-0.34+13.5%
    60d ago$-0.34+13.5%
    30d ago$-0.34+13.0%
    7d ago$-0.39+0.2%
    Current$-0.39
    Revenue Consensus
    $101M
    Range$96M - $104M
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.27
    Range$-0.41 - $-0.21
    11 analysts
    Revenue Consensus
    $121M
    Range$109M - $128M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.27---
    Sep 26EST
    		-$-0.39---
    Jun 26
    Reported Aug 4
    		$-0.47$-0.46-2.17%Miss-34.3%
    Mar 26
    Reported Apr 29
    		$-0.56$-0.56+0.00%Beat-24.4%
    Dec 25
    Reported Feb 25
    		$-0.53$-0.32-63.43%Miss-51.4%
    Sep 25
    Reported Nov 4
    		$-0.38$-0.42+9.52%Beat+5.0%
    Jun 25
    Reported Aug 6
    		$-0.35$-0.41+14.63%Beat+30.0%
    Mar 25
    Reported Apr 24
    		$-0.45$-0.49+8.16%Beat+11.8%
    Dec 24
    Reported Feb 25
    		$-0.35$-0.34-2.94%Miss+35.2%
    Sep 24
    Reported Oct 28
    		$-0.40$-0.49+18.37%Beat+21.6%
    Jun 24
    Reported Aug 1
    		$-0.50$-0.52+3.85%Beat+10.7%
    Mar 24
    Reported May 1
    		$-0.51$-0.56+8.93%Beat+19.0%
    Dec 23
    Reported Feb 27
    		$-0.54$-0.45-20.00%Miss+3.6%
    Sep 23
    Reported Nov 1
    		$-0.51$-0.52+1.92%Beat+0.0%
    Jun 23
    Reported Jul 27
    		$-0.56$-0.56+0.00%Beat-30.2%
    Mar 23
    Reported Apr 27
    		$-0.63$-0.58-8.62%Miss-61.5%
    Dec 22
    Reported Feb 28
    		$-0.56$-0.54-3.70%Miss-33.3%
    Sep 22
    Reported Nov 3
    		$-0.51$-0.52+1.92%Beat-59.4%
    Jun 22
    Reported Aug 4
    		$-0.43$-0.48+10.42%Beat-4.9%
    Mar 22
    Reported May 5
    		$-0.39$-0.47+17.02%Beat+85.2%
    Dec 21
    Reported Mar 8
    		$-0.42$-0.39-7.69%Miss+84.0%
    Sep 21
    Reported Nov 4
    		$-0.32$-0.42+23.81%Beat+89.4%
    Jun 21
    Reported Sep 16
    		$-0.41$-0.40-2.50%Miss+86.5%
    Mar 21
    Reported Jun 30
    		$-2.63$0.00N/AMiss+42.4%
    Dec 20
    Reported Mar 31
    		$-2.63$0.00N/AMiss+42.4%
    Sep 20
    Reported Dec 31
    		$-3.03$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-3.03$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-4.56$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-4.56$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-10.93EV/EBITDA-24.58x
    Price/FCF-14.25xFCF Yield-7.02%
    Profitability
    Profit Margin-32.50%Operating Margin-32.10%
    ROE-30.20%ROIC-27.07%
    Financial Health
    Debt/Equity0.15xInterest Coverage-30.52x
    Current Ratio6.55xQuick Ratio5.35x
    Trading Statistics
    Beta0.89Avg Volume1.53M
    52-Week High$41.5152-Week Low$16.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$21.22
    SMA 20$21.04
    SMA 50$20.32
    SMA 200$26.17
    EMA 10$21.09
    EMA 20$20.87
    EMA 50$21.20
    EMA 200$27.28

    MACD

    Line: 0.24Signal: 0.26Hist: -0.02

    ADX

    ADX: 16.7+DI: 18.3-DI: 16.5

    Aroon & PSAR

    Aroon Up44.0
    Aroon DownN/A
    PSAR$22.49

    Bollinger Bands

    Upper Band$23.04
    Lower Band$19.04
    %B Position1901%(Upper)
    Band Width0.54

    RSI (14-Day)

    Neutral
    52.5

    Momentum Oscillators

    Stoch %K18.6
    Stoch %D26.7
    Williams %R-66.1
    ROC (10d)0.5%
    Momentum0.11
    CCI (20d)-1.6
    MFI (14d)40.5

    Volatility Measures

    ATR (14d)$1.09(5.1%)
    StdDev (20d)1.00
    Hist Vol58.7%(High)

    Volume Flow

    VWAP$20.95
    OBV-51.0M
    AD Line-6.1M
    CMF (20d)0.267

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio0.6x
    VWMA (20d)$20.48

    Pivot Points

    R3$21.61
    R2$21.29
    R1$21.06
    Pivot Point$20.74
    S1$20.51
    S2$20.19
    S3$19.96

    Advanced Oscillators

    TSI5.57
    Ultimate Osc53.9
    KST97.48

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$94.50M$83.13M$76.38M$83.33M$79.18M$69.16M$68.24M$58.37M$53.35M$44.54M$43.58M$35.10M
    Cost of Revenue$32.12M$29.18M$30.07M$29.32M$27.44M$25.00M$24.56M$21.46M$21.87M$19.50M$22.33M$16.23M
    Gross Profit$62.38M$53.95M$46.31M$54.01M$51.75M$44.16M$43.67M$36.91M$31.48M$25.03M$21.25M$18.87M
    Operating Expenses$89.77M$86.55M$77.35M$77.20M$73.94M$71.60M$63.38M$59.34M$58.31M$52.68M$50.81M$44.48M
    R&D$20.10M$21.46M$19.06M$18.19M$17.63M$16.40M$15.07M$16.65M$17.50M$13.08M$14.50M$11.60M
    SG&A$69.67M$65.09M$58.30M$59.01M$56.30M$55.20M$48.32M$42.69M$40.81M$39.60M$36.32M$32.88M
    Operating Income$-27,390,000$-32,606,000$-31,040,000$-23,192,000$-22,189,000$-27,438,000$-19,710,000$-22,427,000$-26,828,000$-27,649,000$-29,559,000$-25,609,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$842,000$818,000$895,000$919,000$895,000$877,000$969,000$1.14M$1.03M$1.04M$1.13M$1.02M
    Income Before Tax$-26,767,000$-31,681,000$-29,656,000$-21,411,000$-19,442,000$-24,784,000$-18,488,000$-20,974,000$-25,626,000$-25,957,000$-27,426,000$-24,622,000
    Income Tax Expense$94,000$-43,000$0$0$136,000$-47,000$0$0$0$0$0$0
    Net Income$-26,861,000$-31,638,000$-29,846,000$-21,411,000$-19,578,000$-24,737,000$-18,856,000$-20,974,000$-25,626,000$-25,957,000$-27,506,000$-24,622,000
    EBITDA$-23,936,000$-29,128,000$-27,052,000$-18,874,000$-16,959,000$-22,432,000$-16,066,000$-18,506,000$-23,327,000$-23,728,000$-24,983,000$-22,549,000
    EBIT$-25,925,000$-30,863,000$-28,761,000$-20,492,000$-18,547,000$-23,907,000$-17,519,000$-19,834,000$-24,596,000$-24,912,000$-26,301,000$-23,603,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRCT

    News

    PRCT INVESTOR DEADLINE: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit Before September 22, 2026 Deadline

    Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for alleged violations of the Securities Exchange Act of 1934. The lawsuit, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, claims that Procept made materially false and/or misleading statements regarding its business, operations, and financial condition between February 28, 2024, and February 25, 2026. Investors who suffered substantial losses are encouraged to seek appointment as lead plaintiff before the September 22, 2026, deadline.

    TMX Newsfile•8/26/26•
    Bearish

    PRCT FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT

    The Rosen Law Firm is reminding purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024, and February 25, 2026, of the September 22, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements regarding its discount program, which artificially inflated sales and revenues by encouraging bulk orders beyond demand, leading to overstocking and significant financial harm. Investors who purchased during the Class Period may be entitled to compensation and are encouraged to contact the law firm to join the class action.

    GlobeNewswire•8/25/26•
    Bearish

    PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

    Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (Procept) with substantial losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding excess field inventory of handpieces, which led to a significant decline in sales and an over 18% drop in stock price. Investors who purchased shares between February 28, 2024, and February 25, 2026, are encouraged to contact KSF for more information.

    TMX Newsfile•8/25/26•
    Bearish

    PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

    Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with substantial losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding inventory issues, specifically that handpiece sales materially exceeded procedures, leading to a significant inventory glut and an 18% stock decline. Investors who purchased shares between February 28, 2024, and February 25, 2026, are encouraged to contact KSF for more information.

    TMX Newsfile•8/24/26•
    Bearish

    PRCT FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT

    The Rosen Law Firm is reminding investors who purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024, and February 25, 2026, about the September 22, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements by failing to disclose a discount program that artificially inflated sales and revenues, leading to an oversupply of products and eventual financial harm. Investors are encouraged to contact the firm to join the class action.

    GlobeNewswire•8/24/26•
    Bearish

    Frequently Asked Questions About PRCT

    Does PRCT pay dividends?
    Procept Biorobotics Corp (PRCT) does not currently pay a regular dividend.
    What is PRCT's market cap?
    Procept Biorobotics Corp (PRCT) has a market capitalization of $1.19B with a current stock price of $21.20.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In